Tafamidis, which stabilises transthyretin, reduces mortality and cardiovascular hospitalisations in cardiac ATTR amyloidosis (phase 3); approved.
Confidence
Established
Level of evidence
●●●●●● Approved by a health authority
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Loss of proteostasisTafamidisTransthyretin amyloidosis (ATTR)
What the sources say
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).